Vor Biopharma (NYSE:VOR) Trading Down 1.3%

Shares of Vor Biopharma Inc. (NYSE:VOR) were down 1.3% during trading on Wednesday . The stock traded as low as $0.98 and last traded at $1.00. Approximately 452,834 shares were traded during trading, an increase of 39% from the average daily volume of 325,283 shares. The stock had previously closed at $1.01.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a report on Thursday, March 21st. Stifel Nicolaus dropped their target price on shares of Vor Biopharma from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. Oppenheimer reiterated an “outperform” rating and set a $10.00 target price (down from $15.00) on shares of Vor Biopharma in a research report on Monday, May 13th. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Vor Biopharma in a report on Friday, May 10th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a report on Monday, May 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $12.50.

Vor Biopharma Trading Down 1.3 %

The stock has a market capitalization of $68.03 million, a P/E ratio of -0.56 and a beta of -0.34. The company has a fifty day simple moving average of $1.29 and a two-hundred day simple moving average of $1.82.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.08). As a group, analysts forecast that Vor Biopharma Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently made changes to their positions in VOR. Exchange Traded Concepts LLC lifted its stake in Vor Biopharma by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 60,170 shares of the company’s stock valued at $135,000 after buying an additional 15,258 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Vor Biopharma in the 1st quarter valued at about $126,000. Finally, Vanguard Group Inc. raised its position in shares of Vor Biopharma by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after acquiring an additional 69,436 shares during the period. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.